Clinical Trials Logo
  1. Home
  2. Apatinib
  3. NCT03365765

mFOLFOX6 Chemotherapy With Apatinib as Postoperative Treatment in Stage IIIB or IIIC Colorectal Cancer

Apatinib Clinical Trial

Official title:
Exploratory Study on the Efficacy and the Safety of mFOLFOX6 Chemotherapy With Apatinib as Postoperative Treatment in Stage IIIB or IIIC Colorectal Cancer

Clinical Trial Summary

This study will focus on postoperative patients of stage IIIB or stage IIIC colorectal cancer. These patients will start to accept chemotherapy in 3-4 weeks after operation, these patients were randomly divided into two groups, one group will accept adjuvant chemotherapy of mFOLFOX6; another group will use mFOLFOX6 combined with apatinib. The efficacy and safety of adjuvant chemotherapy will be compared between the two groups. Disease-free survival, overall survival, incidence of adverse reaction of chemotherapy and postoperative quality of life will be recorded.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03365765
Study type Interventional
Source Huashan Hospital
Contact
Status Completed
Phase Phase 3
Start date February 12, 2018
Completion date December 31, 2022
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT03219593 - Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer Phase 2
Recruiting NCT02544737 - Apatinib for Metastatic Esophageal Cancer. Phase 2
Recruiting NCT05512481 - Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma Phase 2
Recruiting NCT04588987 - Neoadjuvant Carilizumab and Apatinib for Recurrent High-Grade Glioma Phase 2
Not yet recruiting NCT04834674 - DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma Phase 2
Not yet recruiting NCT03889626 - The Maintenance Treatment of Apatinib/Capecitabine Versus Observation in Advanced Gastric Cancer Phase 3
Withdrawn NCT03228043 - Apatinib for Resectable Colorectal Cancer N/A
Recruiting NCT03986515 - Apatinib Plus SHR1210 in Advanced Mucosal Melanoma Phase 2
Recruiting NCT03201146 - Apatinib Combine With Platinum‐Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLC Phase 1/Phase 2
Recruiting NCT03020979 - A Clinical Trial With Apatinib for Subjects With Refractory Malignant Ascites Phase 2
Completed NCT04188847 - First-line Chemotherapy for Recurrent Cervical Cancer Phase 2
Recruiting NCT03428022 - Apatinib Combined With EGFR-TKI for Advanced Slow-progressed EGFR-TKI Resistant NSCLC Phase 3
Active, not recruiting NCT03742193 - Pulmonary Resectable Metastases of Osteosarcoma With Anti-angiogenics and CHemotherapy Phase 2
Recruiting NCT03913182 - Apatinib in the Treatment of Recurrence or Metastasis of Esophageal Cancer Phase 2
Recruiting NCT04180007 - Study of Neoadjuvant Regimen for Radioactive Iodine Treatment of Metastatic and Advanced Differentiated Thyroid Cancers Phase 2